Standard BioTools Inc. (LAB) vs RxSight, Inc. (RXST)
- Standard BioTools Inc. LAB 0.63 −4.55%
- RxSight, Inc. RXST 4.51 −3.43%
Standard BioTools Inc. and RxSight, Inc. are both Medical Devices companies. Standard BioTools Inc. is the larger, with a market value of $258.5M against $194.2M — 1.3× the size. RxSight, Inc. has negative trailing earnings, so its P/E is not meaningful; Standard BioTools Inc. trades at 2.9×. Standard BioTools Inc. grew revenue faster over the last twelve months: 30.2% against −13.3%. Standard BioTools Inc. has the higher net margin (100.4% vs −36.8%) and the lower return on invested capital (−93.9% vs −63.2%). Across the 19 metrics below, Standard BioTools Inc. leads on 10 and RxSight, Inc. on 9.
Valuation
Profitability
| Metric | LAB | RXST | Medical Devices median |
|---|---|---|---|
| Gross margin | 50.49% | 77.50% | 56.01% |
| Operating margin | (112.85%) | (43.20%) | (15.03%) |
| Net margin | 100.37% | (36.80%) | (20.40%) |
| Free cash flow margin | (97.61%) | (21.29%) | (7.24%) |
| Return on equity | 17.61% | (17.35%) | (15.32%) |
| Return on assets | 14.34% | (14.19%) | (19.72%) |
| Return on invested capital | (93.89%) | (63.16%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack